Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer

被引：3

作者：

Teitelbaum, Ursina R. ^{[1
]}

Haller, Daniel G. ^{[1
]}

机构：

[1] Univ Penn, Div Hematol Oncol, Philadelphia, PA 19104 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2009年 / 6卷 / 05期

关键词：

CAPECITABINE PLUS OXALIPLATIN; RANDOMIZED PHASE-III; THERAPY;

D O I：

10.1038/nrclinonc.2009.46

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the movement towards individualized treatment regimens, Rothenberg et al. validate XELOX as another available systemic therapy for patients being treated with second-line treatment for metastatic colorectal cancer. this paper adds to a growing body of data in the first-line and second-line setting that confirms the noninferiority of oral fluoropyrimidine-containing regimens.

引用

页码：250 / 251

页数：3

共 50 条

[41] A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer.
Cho, CD
Fisher, GA
Halsey, J
Jambalos, CN
Schwartz, EJ
Rouse, RV
Advani, RH
Wakelee, HA
Lum, BL
Sikic, BI
CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6103S - 6103S
[42] Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer
Vyzula, R
Kocáková, I
Demlová, R
Kiss, I
Dusek, L
Jarkovsky, J
NEOPLASMA, 2006, 53 (02) : 119 - 127
[43] Metastatic colorectal cancer:: First- and second-line treatment in 2005
Rougier, P
Lepère, C
SEMINARS IN ONCOLOGY, 2005, 32 (06) : S15 - S20
[44] Capecitabine plus oxaliplatin (XELOX) vs. 5-FU/LV + oxaliplatin (FOLFOX4) as second-line treatment for patients with metastatic colorectal cancer (MCRC): Phase III trial results
Rothenberg, M.
Navarro, M.
Butts, C.
Bang, Y.
Cox, J.
Goel, R.
Gollins, S.
Siu, L.
Cunningham, D.
EJC SUPPLEMENTS, 2007, 5 (04): : 238 - 239
[45] Yiqi Zhuyu Decoction(益气逐瘀汤)Combined with FOLFOX-4 as First-Line Therapy in Metastatic Colorectal Cancer
曹波
李绍堂
李志
邓文玲
Chinese Journal of Integrative Medicine, 2011, 17 (08) : 593 - 597+599
[46] A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer
Jianguo Zhi
Eric Chen
Pierre Major
Ivon Burns
Bridget Robinson
Joe McKendrick
Karen Rittweger
Markus Abt
David Goldstein
Cancer Chemotherapy and Pharmacology, 2011, 68 : 1199 - 1206
[47] A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer.
Fishe, GA
Kuo, T
Cho, CD
Halsey, J
Jambalos, CN
Schwartz, EJ
Robert, RV
Advani, RH
Wakelee, HA
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 248S - 248S
[48] Carcinoembryonic antigen in monitoring of response to cetuximab plus FOLFIRI or FOLFOX-4 in patients with metastatic colorectal cancer
Tsai, H. L.
Chang, Y. T.
Chu, K. S.
Chen, C. F.
Yeh, Y. S.
Ma, C. J.
Wu, D. C.
Kuo, C. H.
Chan, H. M.
Sheen, M. C.
Wang, J. Y.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2008, 23 (04): : 244 - 248
[49] Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer
Garrison, L.
Cassidy, J.
Saleh, M.
Lee, F.
Mena, R.
Fuloria, J.
Chang, V.
Ervin, T.
Stella, P.
Saltz, L.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[50] Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy
Huang, Ming-Yii
Huang, Meng-Lin
Chen, Ming-Jenn
Lu, Chien-Yu
Chen, Chin-Fan
Tsai, Pei-Chien
Chuang, Shih-Chang
Hou, Ming-Feng
Lin, Shiu-Ru
Wang, Jaw-Yuan
PHARMACOGENETICS AND GENOMICS, 2011, 21 (01): : 18 - 25

← 1 2 3 4 5 →